OptimizeRx Q4 revenue $28.4M (+44% YoY), non-GAAP net income $4.6M, reiterates 2024 guidance of $100M revenue

OptimizeRx Corp

2024-Q1 EPS reported -$0.38 revenue$19,690,000

Q4 revenue $28.4M (+44% YoY); gross profit $17.8M (63% margin).
GAAP net loss $4.1M ($0.23/share); non-GAAP net income $4.6M ($0.26/share).
Full year revenue $71.5M (+15%); GAAP net loss $17.6M; non-GAAP net income $4.4M.
Adjusted EBITDA Q4 $5.8M (+50% YoY); full year $3.6M.
Reiterates FY2024 guidance: revenue ≥$100M, Adjusted EBITDA ≥$11M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OptimizeRx Corp reported the full year ended December 31, 2023 results: revenue $71.5 million, net income $(17.6) million, EPS $(1.03) per basic and diluted share. Guidance reaffirmed.

Period: the full year ended December 31, 2023
Revenue: $71.5 million
Net income: $(17.6) million
EPS: $(1.03) per basic and diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

cial Highlights ● Revenue in the fourth quarter of 2023 increased 44% to $28.4 million, from $19.7 million in the same period of 2022, with the full year revenue coming in at $71.5 million, a 15% increase when compared to the same year-ago period. ● Gross profit in the fourth quarter of 2023 increased 43% year-over-year to $17.8 million. Gross profit for the full

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OptimizeRx Corp reported the fourth quarter ended December 31, 2023 results: revenue $28.4 million, net income $(4.1) million, EPS $(0.23) per basic and diluted share. Guidance reaffirmed.

Period: the fourth quarter ended December 31, 2023
Revenue: $28.4 million
Net income: $(4.1) million
EPS: $(0.23) per basic and diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Revenue in the fourth quarter of 2023 increased 44% to $28.4 million, from $19.7 million in the same period of 2022, with the full year revenue coming in at $71.5 million, a 15% increase when compared to the same year-ago period.

View on SEC.gov

499 earnings releases filed in the last 30 days. Browse all earnings releases →

OptimizeRx Corp filing history →

Source: SEC EDGAR

accession 0001213900-24-034128

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.